Embecta Corp. (EMBC)
NASDAQ: EMBC · Real-Time Price · USD
5.12
-0.07 (-1.35%)
Sep 18, 2026, 12:28 PM EDT - Market open
Embecta Revenue
Embecta had revenue of $271.70M in the quarter ending June 30, 2026, a decrease of -8.05%. This brings the company's revenue in the last twelve months to $1.02B, down -7.60% year-over-year. In the fiscal year ending September 30, 2025, Embecta had annual revenue of $1.08B, down -3.80%.
Revenue (ttm)
$1.02B
Revenue Growth
-7.60%
P/S Ratio
0.29
Revenue / Employee
$550,649
Employees
1,850
Market Cap
290.10M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 1.08B | -42.70M | -3.80% |
| Sep 30, 2024 | 1.12B | 2.30M | 0.21% |
| Sep 30, 2023 | 1.12B | -8.70M | -0.77% |
| Sep 30, 2022 | 1.13B | -35.80M | -3.07% |
| Sep 30, 2021 | 1.17B | 79.80M | 7.35% |
| Sep 30, 2020 | 1.09B | -23.50M | -2.12% |
| Sep 30, 2019 | 1.11B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| STAAR Surgical Company | 339.59M |
| AngioDynamics | 320.17M |
| OraSure Technologies | 112.41M |
| Sanara MedTech | 109.81M |
| Pro-Dex | 77.55M |
| KORU Medical Systems | 45.11M |
| Utah Medical Products | 36.11M |
| Stereotaxis | 30.07M |
EMBC News
- 17 days ago - embecta to Participate in Investor Events - GlobeNewsWire
- 4 weeks ago - EMBC Stock News: Embecta Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 57% Stock Drop - PRNewsWire
- 5 weeks ago - Kaplan Fox Reminds Embecta Corp. (NASDAQ: EMBC) Investors with Significant Losses to Seek a Leadership Role Before Deadline on August 17, 2026 - GlobeNewsWire
- 5 weeks ago - Kaplan Fox Notifies Embecta Corp. (EMBC) Investors of an Upcoming Lead Plaintiff Deadline on August 17, 2026 - Newsfile Corp
- 5 weeks ago - EMBC Investor Announcement: Embecta Sued on behalf of Investors to Recover Losses after Insulin Pen Issues Lead to 57% Stock Drop - PRNewsWire
- 6 weeks ago - Embecta Earnings Call Transcript: Q3 2026 - Transcripts
- 6 weeks ago - Embecta Earnings release: Q3 2026 - Filings
- 6 weeks ago - Embecta Slides: Q3 2026 - Filings